Physiologically based pharmacokinetic (PBPK) modeling and simulation: Applications in lead optimization

Current Opinion in Drug Discovery and Development

Volumn 12, Issue 4, 2009, Pages 509-518

  Peters, Sheila Annie ^a   Ungell, Anna Lena ^a   Dolgos, Hugues ^a  

^a ASTRAZENECA R AND D   (Sweden)

Author keywords

Data integration; Drug interaction; Human pharmacokinetics; Hypothesis generation; Hypothesis testing; Sensitivity analysis; Whole body physiologically based pharmacokinetic modeling and simulationGL

Indexed keywords

ALPRAZOLAM; CYTOCHROME P450 3A; DILTIAZEM; FUROCOUMARIN; ITRACONAZOLE; KETOCONAZOLE; MIDAZOLAM; SAQUINAVIR; SIMVASTATIN; TRIAZOLAM;

AREA UNDER THE CURVE; CALCULATION; DATA ANALYSIS; DRUG ABSORPTION; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG HALF LIFE; DRUG IDENTIFICATION; DRUG METABOLISM; DRUG RESEARCH; HUMAN; MAXIMUM PLASMA CONCENTRATION; MODEL; NONHUMAN; PARAMETER; PHYSIOLOGICALLY BASED PHARMACOKINETIC MODELING; PHYSIOLOGY; PUBLICATION; REVIEW; SENSITIVITY ANALYSIS; SIMULATION;

ANIMALS; COMPUTER SIMULATION; DRUG DISCOVERY; DRUG INTERACTIONS; HUMANS; MODELS, BIOLOGICAL; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; PHYSIOLOGY;

EID: 67649958146     PISSN: 13676733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (49)

1. Kola I, Landis J: Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov (2004) 3(8):711-715.
2. Peters SA: Evaluation of a generic physiologically based pharmacokinetic model for lineshape analysis. Clin Pharmacokinet (2008) 47(4):261-275. ·· Provides a strategy for the use of PBPK modeling in hypothesis testing.
3. MATLAB - The language of technical computing: The MathWorks Inc, Natick, MA, USA (2009). www.mathworks.com/products/matlab
4. Lüpfert C, Reichel A: Development and application of physiologically based pharmacokinetic-modeling tools to support drug discovery. Chem Biodivers (2005) 2(11):1462-1486. ·· Provides a good overeview of PBPK principles and applications.
5. Product - GastroPlus: Simulations Plus Inc (2009). www.simulationsplus. com/Products.aspx?grpID=3&cID=16&pID=11
6. PK-Sim: Bayer Technology Services GmbH, Leverkusen, Germany (2009). www.pk-sim.com
7. Cloe Predict - Cloe PK Version 2.1: Cyprotex, Macclesfield, UK (2009). www.cyprotex.com/userfiles/file/Cloe%20PK(1).pdf
8. Simcyp: Simcyp Ltd, Sheffield, UK (2009). www.simcyp.com
9. Schmitt W, Willmann S: Physiology-based pharmacokinetic modeling: Ready to be used. Drug Discov Today Tech (2005) 2(1):125-132.
10. Jones HM, Gardner IB, Watson KJ: Modelling and PBPK simulation in drug discovery. AAPS J (2009) 11(1):155-166. ·· An excellent review outlining the application of PBPK as an integrating tool during the lead development stage for the prioritization of compounds for animal PK studies, and at the clinical candidate selection and 'first-inhuman' stages for the prediction of human PKs.
11. Grime KH, Bird J, Ferguson D, Riley RJ: Mechanism-based inhibition of cytochrome P450 enzymes: An evaluation of early decision making in vitro approaches and drug-drug interaction prediction methods. Eur J Pharm Sci (2009) 36(2-3):175-191.
12. Allan G, Davis J, Dickins M, Gardner I, Jenkins T, Jones H, Webster R, Westgate H: Pre-clinical pharmacokinetics of UK-453,061, a novel non-nucleoside reverse transcriptase inhibitor (NNRTI), and use of in silico physiologically based prediction tools to predict the oral pharmacokinetics of UK-453,061 in man. Xenobiotica (2008) 38(6):620-640.
13. Edginton AN, Willmann S: Physiology-based simulations of a pathological condition: Prediction of pharmacokinetics in patients with liver cirrhosis. Clin Pharmacokinet (2008) 47(11):743-752.
14. Edginton AN, Theil FP, Schmitt W, Willmann S: Whole body physiologically-based pharmacokinetic models: Their use in clinical drug development. Expert Opin Drug Metab Toxicol (2008) 4(9):1143-1152.
15. Kato M, Shitara Y, Sato H, Yoshisue K, Hirano M, Ikeda T, Sugiyama Y: The quantitative prediction of CYP-mediated drug interaction by physiologically based pharmacokinetic modeling. Pharm Res(2008) 25(8):1891-1901.
16. Peters SA: Identification of intestinal loss of a drug through physiologically based pharmacokinetic simulation of plasma concentration-time profiles. Clin Pharmacokinet (2008) 47(4):245- 259. · Illustrates an application of PBPK for hypothesis testing.
17. Peters SA, Hultin L: Early identification of drug-induced impairment of gastric emptying through physiologically based pharmacokinetic (PBPK) simulation of plasma concentrationtime profiles in rat. J Pharmacokinet Pharmacodyn (2008) 35(1):1-30.
18. Einolf HJ: Comparison of different approaches to predict metabolic drug-drug interactions. Xenobiotica (2007) 37(10-11):1257- 1294.
19. Lavé T, Parrott N, Grimm HP, Fleury A, Reddy M: Challenges and opportunities with modelling and simulation in drug discovery and drug development. Xenobiotica (2007) 37(10-11):1295-1310.
20. Andersson S, Armstrong A, Björe A, Bowker S, Chapman S, Davies R, Donald C, Egner B, Elebring T, Holmqvist S, Inghardt T et al: Making medicinal chemistry more effective - Application of Lean Sigma to improve processes, speed and quality. Drug Discov Today(2009):doi:10.1016/j. drudis.2009.03.005.
21. Ungell A-L: In vitro absorption studies and their relevance to absorption from the GI tract. Drug Dev Ind Pharm (1997) 23:879-892.
22. Amidon GL, Lennernäs H, Shah VP, Crison JR: A theoretical basis for a biopharmaceutic drug classification: The correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res (1995) 12(3):413-420.
23. Oprea TI, Zamora I, Ungell AL: Pharmacokinetically based mapping device for chemical space navigation. J Comb Chem(2002) 4(4):258-266.
24. Kwon H, Lionberger RA, Yu LX: Impact of P-glycoproteinmediated intestinal efflux kinetics on oral bioavailability of P-glycoprotein substrates. Mol Pharm (2004) 1(6):455-465.
25. Germani M, Crivori P, Rocchetti M, Burton PS, Wilson AG, Smith ME, Poggesi I: Evaluation of a basic physiologically based pharmacokinetic model for simulating the first-time-in-animal study. Eur J Pharm Sci (2007) 31(3-4):190-201.
26. Cai H, Stoner C, Reddy A, Freiwald S, Smith D, Winters R, Stankovic C, Surendran N: Evaluation of an integrated in vitro-in silico PBPK (physiologically based pharmacokinetic) model to provide estimates of human bioavailability. Int J Pharm (2006) 308(1-2):133-139.
27. Theil FP, Guentert TW, Haddad S, Poulin P: Utility of physiologically based pharmacokinetic models to drug development and rational drug discovery candidate selection. Toxicol Lett (2003) 138(1-2):29-49.
28. Parrott N, Jones H, Paquereau N, Lavé T: Application of full physiological models for pharmaceutical drug candidate selection and extrapolation of pharmacokinetics to man. Basic Clin Pharmacol Toxicol (2005) 96(3):193-199.
29. Parrott N, Paquereau N, Coassolo P, Lavé T: An evaluation of the utility of physiologically based models of pharmacokinetics in early drug discovery. J Pharm Sci (2005) 94(10):2327-2343.
30. De Buck SS, Sinha VK, Fenu LA, Nijsen MJ, Mackie CE, Gilissen RA: Prediction of human pharmacokinetics using physiologically based modelling: A retrospective analysis of 26 clinically tested drugs. Drug Metab Dispos (2007) 35(10):1766-1780.
31. Allan G, Davis J, Dickins M, Gardner I, Jenkins T, Jones H, Webster R, Westgate H: Pre-clinical pharmacokinetics of UK-453,061, a novel non-nucleoside reverse transcriptase inhibitor (NNRTI), and use of in silico physiologically based prediction tools to predict the oral pharmacokinetics of UK-453,061 in man. Xenobiotica (2008) 38(6):620-640.
32. Jones HM, Parrott N, Jorga K, Lavé T: A novel strategy for physiologically based predictions of human pharmacokinetics.Clin Pharmacokinet (2006) 45(5):511-542.
33. Feng MR, Lou X, Brown RR, Hutchaleelaha A: Allometric pharmacokinetic scaling: Towards the prediction of human oral pharmacokinetics. Pharm Res (2000) 17(4):410-418.
34. Davda JP, Jain M, Batra SK, Gwilt PR, Robinson DH: A physiologically based pharmacokinetic (PBPK) model to characterize and predict the disposition of monoclonal antibody CC49 and its single chain Fv constructs. Int Immunopharmacol (2008) 8(3):401-413.
35. Heiskanen T, Heiskanen T, Kairemo K: Development of a PBPK model for monoclonal antibodies and simulation of human and mice PBPK of a radiolabelled monoclonal antibody. Curr Pharm Des (2009) 15(9):988-1007.
36. Gueorguieva I, Nestorov IA, Rowland M: Reducing whole body physiologically based pharmacokinetic models using global sensitivity analysis: Diazepam case study. J Pharmacokinet Pharmacodyn (2006) 33(1):1-27.
37. Nestorov IA, Aarons LJ, Rowland M: Physiologically based pharmacokinetic modeling of a homologous series of barbiturates in the rat: A sensitivity analysis. J Pharmacokinet Biopharm (1997) 25(4):413-447. · Describes sensitivity analysis in PBPK models.
38. Thomas S, Brightman F, Gill H, Lee S, Pufong B: Simulation modelling of human intestinal absorption using Caco-2 permeability and kinetic solubility data for early drug discovery.J Pharm Sci (2008) 97(10):4557- 4574.
39. Sui X, Sun J, Wu X, Li H, Liu J, He Z: Predicting the volume of distribution of drugs in humans. Curr Drug Metab (2008) 9(6):574-580.
40. Hutzler M, Messing DM, Wienkers LC: Predicting drug-drug interactions in drug discovery: Where are we now and where are we going? Curr Opin Drug Discov Dev (2005) 8(1):51-58.
41. Rostami-Hodjegan A, Tucker GT: In silico simulations to assess the in vivo consequences of in vitro metabolic drug-drug interactions. Drug Discov Today Tech (2004) 1(4):441-448. · Provides a good overview of a PBPK approach to DDI risk assessment.
42. FDA: Drug interaction studies - Study design, data analysis, and implications for dosing and labeling. FDA Center for Drug Evaluation and Research, Rockville, MD, USA (2006). www.fda.gov/ cder/Guidance/6695dft.pdf
43. Blanchard N, Richert L, Coassolo P, Lavé T: Qualitative and quantitative assessment of drug-drug interaction potential in man, based on Ki, IC50 and inhibitor concentration. Curr Drug Metab (2004) 5(2):147-156.
44. Wang YH, Jones DR, Hall SD: Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites.Drug Metab Dispos (2004) 32(2):259-266.
45. Obach RS, Walsky RL, Venkatakrishnan K: Mechanism-based inactivation of human cytochrome p450 enzymes and the prediction of drug-drug interactions. Drug Metab Dispos (2007) 35(2):246-255.
46. Ernest CS 2nd, Hall SD, Jones DR: Mechanism-based inactivation of CYP3A by HIV protease inhibitors. J Pharmacol Exp Ther (2005) 312(2):583-591.
47. Fenneteau F, Poulin P, Nekka F: Physiologically based predictions of the impact of inhibition of intestinal and hepatic metabolism on human pharmacokinetics of CYP3A substrates. J Pharm Sci(2009):doi:10.1002/ jps.21802.
48. Chenel M, Bouzom F, Aarons L, Ogungbenro K: Drug-drug interaction predictions with PBPK models and optimal multiresponse sampling time designs: Application to midazolam and a phase I compound. Part 1: Comparison of uniresponse and multiresponse designs using PopDes. J Pharmacokinet Pharmacodyn (2008) 35(6):635-659.
49. Chenel M, Bouzom F, Cazade F, Ogungbenro K, Aarons L, Mentré F: Drug-drug interaction predictions with PBPK models and optimal multiresponse sampling time designs: Application to midazolam and a phase I compound. Part 2: Clinical trial results. J Pharmacokinet Pharmacodyn (2008) 35(6):661-681.